DDInter1259 DDInter1581
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Anaphylactoid reaction
Anaphylactoid reaction {u} (Side Effect) is caused by {v} (Compound) Repaglinide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may lead to a major life threatening interaction when taken with {v} Repaglinide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Repaglinide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may lead to a major life threatening interaction when taken with {v} Repaglinide
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Anaphylactoid reaction
Anaphylactoid reaction {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Repaglinide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} (Compound) causes {v} (Side Effect) Chest pain
Chest pain {u} (Side Effect) is caused by {v} (Compound) Repaglinide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Rosoxacin
Rosoxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Repaglinide
Nalidixic acid (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Repaglinide (Compound)
Nalidixic acid (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may lead to a major life threatening interaction when taken with Repaglinide
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may lead to a major life threatening interaction when taken with Repaglinide
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may lead to a major life threatening interaction when taken with Repaglinide
Nalidixic acid (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Nalidixic acid (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Nalidixic acid (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Repaglinide
Nalidixic acid (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Nalidixic acid (Compound) resembles Rosoxacin (Compound) and Rosoxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may lead to a major life threatening interaction when taken with Repaglinide